

AMENDMENTS TO THE CLAIMSComplete Listing of the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 14. (Cancelled).

15. (Cancelled).

16. - 17. (Cancelled).

18. (Previously Presented) A compound as defined by Formula I:



**Formula I**

in which;

R<sub>1</sub> and R<sub>2</sub> are the same or different and independently selected from hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> substituted alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>1</sub>-C<sub>10</sub> alkenoxy, C<sub>1</sub>-C<sub>10</sub> alkynoxy, C<sub>1</sub>-C<sub>10</sub> alkylthio, C<sub>1</sub>-C<sub>10</sub> alkenylthio, C<sub>1</sub>-C<sub>10</sub> alkynylthio, C<sub>6</sub>-C<sub>10</sub> arylthio, C<sub>1</sub>-C<sub>10</sub> alkylsulphone, C<sub>1</sub>-C<sub>10</sub> alkenylsulphone, C<sub>1</sub>-C<sub>10</sub> alkynylsulphone, C<sub>6</sub>-C<sub>10</sub> arylsulphone, C<sub>1</sub>-C<sub>10</sub> alkylsulphoxide, C<sub>1</sub>-C<sub>10</sub> alkenylsulphoxide, C<sub>1</sub>-C<sub>10</sub> alkynylsulphoxide, C<sub>6</sub>-C<sub>10</sub> arylsulphoxide, C<sub>1</sub>-C<sub>10</sub> alkylarylthio, C<sub>1</sub>-C<sub>10</sub> alkylarylsulphone,

C<sub>1</sub>-C<sub>10</sub> alkylarylsulphoxide, C<sub>6</sub>-C<sub>10</sub> aryl, or C<sub>5</sub>-C<sub>20</sub> heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R<sup>a</sup> which groups may be the same or different; or R<sub>1</sub> and R<sub>2</sub> may together form a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group;

R<sub>3</sub> and R<sub>4</sub> are the same or different and independently selected from hydrogen, halogen, C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkenoxy, C<sub>1</sub>-C<sub>4</sub> alkynoxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkenylthio, C<sub>1</sub>-C<sub>4</sub> alkynylthio C<sub>1</sub>-C<sub>10</sub> alkylsulphone, C<sub>1</sub>-C<sub>10</sub> alkenylsulphone, C<sub>1</sub>-C<sub>10</sub> alkynylsulphone, C<sub>6</sub>-C<sub>10</sub> arylsulphone, C<sub>1</sub>-C<sub>10</sub> alkylsulphoxide, C<sub>1</sub>-C<sub>10</sub> alkenylsulphoxide, C<sub>1</sub>-C<sub>10</sub> alkynylsulphoxide, C<sub>1</sub>-C<sub>10</sub> arylsulphoxide, C<sub>1</sub>-C<sub>10</sub> alkylarylsulphoxide, C<sub>6</sub>-C<sub>15</sub> aryl, C<sub>5</sub>-C<sub>20</sub> heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R<sup>a</sup> which groups may be the same or different; or can together form a keto group;

R<sub>5</sub> is chosen from nitro, cyano, -CH<sub>2</sub>CN, -COMe, or -SO<sub>2</sub>CH<sub>3</sub>;

R<sub>6</sub> is chosen from the group consisting of; hydrogen, C<sub>1</sub>-C<sub>5</sub> alkyl, halogen, CN, CO<sub>2</sub>H, CHF<sub>2</sub>, CH<sub>2</sub>F or CF<sub>3</sub>;

R<sub>8</sub> is chosen from the group consisting of; hydrogen, C<sub>1</sub>-C<sub>5</sub> alkyl, halogen, CHF<sub>2</sub>, CH<sub>2</sub>F or CF<sub>3</sub>;

X is -NH-;






Y is chosen from hydroxy, or -NH(C<sub>1</sub>-C<sub>10</sub> heteroaryl);


Z is chosen from CR<sub>7</sub> or N;

R<sub>7</sub> is H or C<sub>1</sub>-C<sub>5</sub> alkyl;

R<sup>a</sup> represents a member selected from: hydrogen, halogen, -CN, OH, CO<sub>2</sub>H, CHO, NO<sub>2</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub>), N(C<sub>1</sub>-C<sub>4</sub>)<sub>2</sub>, -NH(C<sub>6</sub>aryl), -N(C<sub>6</sub>aryl)<sub>2</sub>, -NH(C<sub>5</sub>-C<sub>10</sub> heteroaryl), and -N(C<sub>5</sub>-C<sub>10</sub> heteroaryl)<sub>2</sub>; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:





wherein A is -CN or -NO<sub>2</sub>, B is -CN, -NO<sub>2</sub> or -SO<sub>2</sub>CH<sub>3</sub>, and D is hydrogen or methyl.

19. (Original) A compound according to claim 18, wherein R<sub>1</sub> or/and R<sub>2</sub> are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH<sub>2</sub>)<sub>2</sub>SMe, (R)-CH<sub>2</sub>SCH<sub>2</sub>Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.
20. (Previously Presented) A compound according to claim 18, wherein R<sub>3</sub> is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R<sub>4</sub>.
21. (Previously Presented) A compound according to claim 18, wherein R<sub>4</sub> is H, methyl, or forms a keto group together with R<sub>3</sub>.
22. (Previously Presented) A compound according to claim 18, wherein R<sub>5</sub> is NO<sub>2</sub>, CN, or CH<sub>2</sub>CN.

23. (Previously Presented) A compound according to claim 18, wherein R<sub>6</sub> is Me or CF<sub>3</sub>.
24. (Previously Presented) A compound according to claim 18, wherein R<sub>7</sub> is H or Me.
25. (Previously Presented) A compound according to claim 18, wherein R<sub>8</sub> is H or methyl.
26. (Cancelled)
27. (Previously Presented) A compound according to claim 18, wherein Y is -OH.
28. (Cancelled)
29. (Previously Presented) A compound according to claim 18, wherein the compound is chosen from the group consisting of:  
2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-ol;  
[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol  
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-propan-1-ol;  
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;  
2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;  
[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;  
(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;  
2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;

[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;

(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;

(S)-2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;

(DL)-3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-ol;

(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;

4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;


[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;










6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;  
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;  
and compounds having the formula:



in which R<sub>9</sub>, R<sub>6</sub> and Z are as defined in the following table:







R9	R6	Z
	CF <sub>3</sub>	CH

R9	R6	Z
	CF <sub>3</sub>	CH

R9	R6	Z
	CF <sub>3</sub>	CH
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N
	CH <sub>3</sub>	N

R9	R6	Z
	CH <sub>3</sub>	N

R9	R6	Z
	CH <sub>3</sub>	N
	CH <sub>3</sub>	CH
	CH<	

R9	R6	Z
	CH <sub>3</sub>	CH
	CH <sub>3</sub>	CH
	CH <sub>3</sub>	CH
	CH <sub>3</sub>	CH
	CH <sub>3</sub>	CH
	CH <sub>3</sub>	CH

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol  
2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol  
3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol  
[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol  
2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol  
2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol  
4-((R)-1-Benzylsulfanyl-methyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile  
(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol  
4-((R)-2-Hydroxy-1-phenylmethanesulfinyl-methyl-ethylamino)-2-trifluoromethyl-benzonitrile  
[1-(4-Nitro-phenylamino)-cyclopentyl]-methanol  
(S)-2-(4-Nitro-phenylamino)-pentan-1-ol  
[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol  
(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol  
(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

30. (Previously Presented) A compound according to claim 18, wherein R<sub>1</sub> or R<sub>2</sub> is a C<sub>6</sub>-C<sub>10</sub> arythio comprising an aryl-substituted sulfur-containing C<sub>1</sub>-C<sub>10</sub> alkyl group.

31. (Previously Presented) A compound according to claim 18, wherein in R<sub>1</sub> or R<sub>2</sub> the alkylsulfur is substituted with a C<sub>6</sub> aryl group.

32 - 43. (Cancelled)

44. (New) A pharmaceutical composition containing a compound according to claim 18.